Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 13 min ago
Peer-reviewedCC BY-NC-NDTranslational andrology and urology

Fibroblast growth factor receptor inhibitors for non-muscle-invasive bladder cancer: THOR-2 and beyond.

  • Albert Jang1,2
  • Beaux Mitchell3
  • Jason R Brown4,5
  • Vadim S Koshkin3,6
6 affiliations
  1. 1Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  2. 2Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  3. 3UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  4. 4Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  5. 5Case Comprehensive Cancer Center, Cleveland, OH, USA.
  6. 6Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
Read full textPDFDOICite

Related

  1. Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis
    Zhe Wang, Bo Shao, Danxue Huang +1
    Frontiers in pharmacologyPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCCrossref
  2. Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial
    Tanios Bekaii‐Saab, Davide Melisi, Hanneke W. Wilmink +24
    Journal of Clinical OncologyPeer-reviewedLicence not statedFull text10 citedSurgery & anaesthesiaOpenAlex
  3. Factors Influencing the Treatment Response of Tetracyclines for Papulopustular Rash Induced by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Study.
    Tae Min Kim, Namkyu Kim, Jimin Woo +3
    Dermatology practical & conceptualPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review
    Naoto Minematsu, Yoko Imai, Toshiyuki Hirano +1
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  5. Practical Pathological Assessment of Residual Cancer Burden (RCB) After Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Invasive Breast Carcinoma: A Case Report.
    Gunvanti Rathod, Chandramouli R, Immanuel Pradeep +1
    CureusPeer-reviewedCC BYFull textOncologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{jang2026fibroblast,
  title = {{Fibroblast growth factor receptor inhibitors for non-muscle-invasive bladder cancer: THOR-2 and beyond.}},
  author = {Albert Jang and Beaux Mitchell and Jason R Brown and Vadim S Koshkin},
  journal = {Translational andrology and urology},
  year = {2026},
  month = oct,
  doi = {10.21037/tau-2026-0649},
  url = {https://europepmc.org/article/MED/42997194},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Fibroblast growth factor receptor inhibitors for non-muscle-invasive bladder cancer: THOR-2 and beyond.
AU  - Albert Jang
AU  - Beaux Mitchell
AU  - Jason R Brown
AU  - Vadim S Koshkin
PY  - 2026
DA  - 2026/10/22
JO  - Translational andrology and urology
DO  - 10.21037/tau-2026-0649
UR  - https://europepmc.org/article/MED/42997194
SN  - 2223-4691
ER  -